NAT is associated with a higher rate of achieving R0 margins [11,12] and may control micrometastatic disease; thus, it is important to determine whether NAT influences patterns of treatment failure in terms of the frequency and site of recurrent cancer. This evidence concerns the gene BRD2 and cancer.